Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Finished

Sugar-enabledVAC Glycoengineered erythrocytes for better influenza vaccines

Coordinator
Universiteit Utrecht, Netherlands
Runs
1 September 2022 to 29 February 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101081818

What the project is doing

In the project's own words, from its summary on CORDIS.

The objective of this ERC PoC project is to establish technical and commercial feasibility of our recently developed glycan-engineered red blood cells (RBCs) for antigenic characterization of circulating influenza A/H3N2 viruses. Due to the rapid evolution of influenza A/H3N2 viruses, antigenic characterization by the widely used hemagglutination inhibition (HI) assay is not possible anymore. Continuous antigenic characterization of influenza A viruses is, however, essential for the development of protective seasonal vaccines.

The ERC program “sugar-enable” has developed glycoengineered RBCs that make it possible again to antigenically characterize circulating A/H3N2 viruses by the standard HI assay, and it is expected that the cells will find application in hundreds of laboratories worldwide.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit UtrechtUtrechtNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI